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based on the same clinical studies and corresponded to improvement in respira-
tory symptoms (as measured by the CFQ-R). In one case, the improvement in res-
piratory symptoms was considered as primary endpoint (aztreonam lysine – one 
study). ConClusions: There are few PRO labeling claims in products approved for 
CF in Europe and the United States. Discrepancies exist in the CF guidance issued by 
the FDA and the EMA, where EMA is more favorable to PRO endpoints.
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Pain-Related diSabilitY, Self-efficacY, and coPing StRategieS of 
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objeCtives: Chronic low back pain is a persistent disabling condition that impairs 
the individual’s functional status and poses as an economic burden to the society. 
The objectives of this study were to examine the pain-related disability, self-effi-
cacy and coping strategies of adult patients with chronic low back pain and their 
relationships, the differences in pain-related disability, self-efficacy and coping 
strategies used among socio-demographic and clinical characteristic subgroups, 
and to identify the predictors of pain-related disability. Methods: A descriptive, 
correlational questionnaire survey design was used. A convenience sample of 65 
patients aged 21 years or above with a diagnosis of chronic low back pain was 
recruited from a public hospital in Singapore from September 2012 to January 2013. 
Roland-Morris Disability Questionnaire, Chronic Low Back Pain Self-Efficacy Scale, 
and Coping Strategies Questionnaire-24 were used to collect data. Descriptive statis-
tics, independent sample t-test, analysis of variance, and Peanson Product-moment 
Correlation Coefficent were used to analyse the data. Results: The participants 
had moderate levels of pain-related disability and self-efficacy, and used both active 
and passive coping strategies. Significant differences in pain-related disability, self-
efficacy and coping strategies used were found among subgroups of various socio-
demographics. Significant differences in pain-related disability were found within 
one subgroup of clinical variable. Pain-related disability had a significant negative 
relationship with self-efficacy and positive relationship with passive coping, while 
self-efficacy had a significant positive relationship with active coping and a nega-
tive relationship with passive coping. Self-efficacy, ethnicity and monthly income 
were predictors of pain-related disability. ConClusions: Our findings indicate 
the need to enhance patients’ self-efficacy and reduce the use of passive coping 
strategies in order to decrease pain-related disability. Future intervention studies 
improving patients’ self-efficacy and coping are needed to improve patients’ well-
being and quality of life.
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objeCtives: Patient-reported measures of Vaso Occlusive Crisis (VOC) outcomes 
reported in literature were identified and quality of evidence for each type of meas-
ure was assessed. Methods: PubMed, COCHRANE and CINAHL databases (1966 
through August 2012) and reference lists of identified articles were searched for any 
patient-reported measures employed to assess VOC outcomes. Identified measures 
were categorized as: measures assessing pain, and measures assessing quality of 
life (QoL) due to VOC. Studies were assessed for quality of evidence based on risk 
of bias (coded ‘1’ for randomized controlled study without any serious limitations, 
else ‘0’), consistency (coded ‘1’ for demonstrated clinical and methodological homo-
geneity, else ‘0’), directness (coded ‘1’ for use of non-surrogate endpoint, else ‘0’) 
and precision (coded ‘1’ if total number of cases across all studies of measure was 
greater than 400, else ‘0’). Overall quality of evidence was calculated by summation 
of each domain score, where ‘4’ meant ‘high,’ ‘3,’ ‘moderate,’ ‘2,’ ‘low’ and scores 
less than or equal to ‘1’ denoted ‘very low’ quality of evidence. Results: A total of 
1,620 potentially relevant studies were identified and reviewed. Of those, 63 stud-
ies passed inclusion criteria and were retained for analyses. Twenty-three unique 
patient-reported measures of VOC outcomes were identified and categorized. Fifty-
seven studies employed pain based measures and 12 studies employed QoL based 
measures. While, overall mean quality of evidence score was 2.17, mean quality of 
evidence score for pain based measures was 2.35 and for QoL based measures was 
1.42. The most commonly employed pain based measures were Visual Analog Scales 
(VAS), (28 studies), whereas, the most commonly employed QoL based measure was 
school/work attendance, (4 studies). ConClusions: A variety of patient-reported 
measures of VOC outcomes were identified and categorized. VAS, and face based 
scales had higher quality of evidence compared to measure of school/work attend-
ance.
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objeCtives: 1) To identify products indicated for the treatment of rare diseases 
approved through the centralized procedure in Europe, and (2) To list the products 
which obtained a PRO labeling claim. Methods: The search was performed on 
the European Medicines Agency (EMA) website (11/12/2013). The European public 
assessment reports (EPARs) were browsed by type (i.e., orphan medicines). Products 
refused were excluded. Then, the PROLabels database was searched for each product 
retrieved to identify any PRO claim in the corresponding label. Results: A total of 
69 orphan medicines were identified on the EMA website, representing 11 different 
objeCtives: Despite the clearly evident better clinical outcomes with prophy-
laxis compared to on-demand therapy, on average only 55% of patients diagnosed 
with severe hemophilia receive prophylactic factor replacement therapy in the US. 
Prophylaxis generally drops with age, partly due to patients becoming more inde-
pendent and less compliant as they reach adulthood and partly due to reduced 
perceived benefit. High treatment costs of prophylaxis therapy also remains a 
barrier. Further, the development of long-acting factor products offering a mod-
est improvement in convenience is likely to drive-up treatment costs. This study 
aims to understand hemophilia patient preferences and their willingness-to-pay 
for hemophilia therapies (on-demand, standard prophylaxis, longer-acting prophy-
laxis). Methods: U.S. adult patients and caregivers of children with hemophilia (n 
= 79) completed a discrete-choice survey that presented a series of trade-off ques-
tions, each including a pair of hypothetical treatment profiles, that had an assigned 
cost for attaining improvement in health states. The relative importance of treat-
ment attributes such as out-of-pocket treatment costs, dose adjustment, treatment 
related complications and clinical efficacy & dosing regimen was analyzed using 
mixed logit models. Based on the attribute estimates, patients’ WTP was deter-
mined. Results: Out-of-pocket treatment costs (P < .001), treatment complications 
(P < .001) and clinical efficacy & dosing regimen (P < .001) were perceived to be the 
most important treatment attributes. Patients were willing to pay on average $150 
per/month for improvement in each of the prophylaxis dosing regimens (i.e. 3 times 
weekly vs 2 times weekly vs. 1 time weekly vs. 1 time in two weeks). ConClusions: 
The results suggest that patients are willing to pay more for improvements in treat-
ment related complications, clinical efficacy & dosing regimen. These estimates of 
patients’ willingness-to-pay can be used to provide guidelines for resource alloca-
tion. Literature also suggests that patient preferences are likely to directly translate 
into increased treatment adherence, leading to greater treatment effectiveness.
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objeCtives: Phenylketonuria (PKU) is the most common in-born error of metabo-
lism and is associated with neuropsychiatric sequelae. Interviews among adults 
and parents of children with PKU have established that inattentiveness is an 
important psychiatric symptom. Although the Adult ADHD Self-Rating Scale (ASRS; 
self-report) and ADHD Rating Scale (ADHD RS-IV; parent-report) instruments have 
been validated for measuring symptoms of inattentiveness in persons with ADHD, 
their psychometric value for measuring PKU-related inattentiveness has not been 
established. This study investigated the psychometric properties of the ASRS and 
ADHD RS-IV inattentiveness subscales in a PKU population ≥ 8 years old. Methods: 
A post-hoc analysis was conducted in participants ≥ 8 years of age in a Phase 3b 
double blind, placebo-controlled clinical trial in PKU over a 13-week period. The 
ASRS/ADHD RS-IV reliability, construct validity, and responsiveness were meas-
ured using clinician- and adult-/parent-reported outcomes collected in this clini-
cal trial. Results: Data analysis revealed strong internal consistency reliability 
for both measures (α ≥ 0.87). In addition, the test-retest analyses resulted in ICCs 
≥ 0.87, indicating outstanding agreement between the Baseline and Week 4 (re-test 
visit) measures for both the adult- and parent-rated inattentiveness subscales. Both 
inattentiveness measures demonstrated an ability to discriminate between known 
groups (p< 0.0001) defined by the Clinical Global Impression-Severity (CGI-S) scale. 
Correlations between the ASRS/ADHD RS-IV with the CGI-S and age-appropriate 
Behavior Rating Inventory of Executive Function (BRIEF) Working Memory subscale 
were consistently moderate-to-strong (r ≥ 0.56). Similarly, results of the change score 
correlations were moderate (r ≥ 0.43) for both measures when compared to changes 
over time in the BRIEF Working Memory subscale. ConClusions: These findings 
of reliability, validity, and responsiveness of both the ASRS and the ADHD RS-IV 
inattentiveness sub-scales, in addition to content validation results, further support 
their use for the assessment of inattentive symptoms among persons with PKU ≥ 8 
years old in clinical trials.
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objeCtives: The objective of this research was to review the role of patient-reported 
outcomes (PROs) in drug approval and labeling of products authorized for the treat-
ment of cystic fibrosis (CF) in Europe and in the United States. Methods: This 
research was conducted through a systematic manual review of CF specific regula-
tory guidelines and product labelings (US and EU). The PROLabels database was used 
for the label review. FDA medical reviews and EMA assessment reports were also 
used to review the clinical studies performed for regulatory approval. Results: 
In its guideline specific to CF, the EMA recommends the use of the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R) and labels it as a quality-of-life endpoint. The CFQ-R 
is a disease-specific instrument designed to measure impact on overall health, 
daily life, perceived well-being and symptoms. There is no specific FDA guidance 
on CF: the corresponding FDA guidance only covers exocrine pancreatic insuffi-
ciency drug products and recommends steatorrhea as the main endpoint. A total of 
seven different products (seven brand names, six INN) indicated for the treatment 
of cystic fibrosis were identified: five were approved by the EMA, and five by the 
FDA. Three products were common to both agencies: aztreonam lysine, ivacaftor 
and tobramycin. Two products were identified with a PRO claim in Europe and in 
the United States, i.e., aztreonam lysine and ivacaftor. In both cases, the claim was 
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Behavioral Risk Factor Surveillance System (BRFSS) for New Mexico (NM) in which 
self-reported health status was measured on a 5-point scale of poor to excellent. For 
the purpose of this study we dichotomized self-reported health into 2 categories: 
good (good, very good, and excellent) and poor (fair and poor). Propensity score 
model of 13 variables accounting for socioeconomic factors, disease status, and 
exercise behavior was used to match obese (body mass index (BMI) ≥ 30 kg/m2) indi-
viduals with non-obese (BMI < 30 kg/m2).We used the STATA command psmatch2 
to perform 1:1 nearest neighbor matching without replacement, and caliper width 
was set at 0.001. Adequacy of matching was assessed by estimating the standardized 
differences between obese and non-obese individuals for all variables. Self-reported 
health was compared between the 2 groups using the McNemar’s test for matched 
comparison. Results: We identified 2310 obese individuals (26%) and 6671 non-
obese individuals (74%) in the database. Obese individuals were significantly dif-
ferent from non-obese in nearly all baseline characteristics. After 1:1 propensity 
score matching (n = 3512), obese individuals were significantly more likely to report 
poor health compared to non-obese individuals (Odds ratio = 1.45, 95% confidence 
interval: 1.23-1.72, p< 0.001).All standardized differences between groups were < 10% 
suggesting and adequate matching. ConClusions: Among propensity-matched 
individuals, those with obesity are more likely to rate their health as poor compared 
to non-obese individuals. Continuing efforts are needed to fight obesity epidemic 
both locally and nationally to improve overall quality of life.
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objeCtives: To examine the effect of factor IX concentrate consumption on self/
parent-proxy reported health status among persons with hemophilia B. Methods: 
Data were obtained from the Hemophilia Utilization Group Study Part Vb (HUGS 
Vb), a prospective, multi-center observational study evaluating burden of illness 
among a US hemophilia B population who obtain care at Hemophilia Treatment 
Centers. Health status was assessed using a visual analogue scale (VAS) at initial 
interview and at two-year follow-up visits. A clinically meaningful improvement in 
health status was defined as an increase of > 7 in VAS score. Annual factor concen-
trate consumption was estimated using 2 years of dispensing records. Propensity 
score matching (PSM) was applied to adjust for potential selection bias between 
persons with high (≥ 5000 IU/kg/yr) and low (< 5000 IU/kg/yr) factor consumption. 
Age, disease severity, treatment regimen and bleeding frequency were included 
in the propensity score model. Results: After applying PSM, mean age in the 
high (n= 25, 20 severe) and low factor consumption (n= 25, 21 severe) groups were 
14.5±11.6 and 14.3±11.3, respectively. The average bleeding rates were 7.4±6.6 and 
7.2±7.8 per year correspondingly. The proportion of participants treated with pro-
phylactic therapy was 64% in both groups. On average, persons with high factor 
consumption reported greater (1.96±15.48) VAS score changes than those with low 
factor consumption. Among persons with VAS< 93 at baseline (n= 34), 14 participants 
reported a clinically meaningful improvement in VAS after 2 years. The propor-
tion of participants who reported a clinically meaningful improvement was greater 
among persons in the high consumption group than in the low consumption group 
(50% vs. 35%). ConClusions: Due to the small sample size, regression was not 
performed to show the independent relationship between health status and factor 
consumption. However, persons using > 5000 IU/kg/yr of factor tend to report greater 
improvement in health status.
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objeCtives: Improvements in health-related quality of life (HRQoL) with epratu-
zumab (a monoclonal antibody targeting CD22) have been reported in patients with 
systemic lupus erythematosus (SLE) in the ALLEVIATE trials from Week 12 to 4 
years. In the EMBLEM™ dose-ranging, phase IIb, randomized controlled trial in SLE, 
epratuzumab resulted in clinically-relevant improvements in disease activity. We 
report HRQoL data from EMBLEM™ and its open-label extension (OLE). Methods: 
In EMBLEM™, patients with moderate-to-severe SLE (≥ 1 BILAG 2004 A or ≥ 2 Bs) were 
randomized to placebo (PBO) or epratuzumab (cumulative dose [cd] 200, 800, 2400 or 
3600mg divided every other week, or 600mg every week), plus standard of care (SOC). 
Patients who completed 12 weeks or discontinued due to lack of efficacy after ≥ 8 
weeks were eligible for OLE (1200mg epratuzumab at Weeks 0,2 of 12-week cycles). 
HRQoL was assessed using Short Form-36 (SF-36) v2.0. Data are reported to the end 
of EMBLEM™ and OLE Weeks 48 and 108. Mean changes and % patients reporting 
improvements ≥ minimum clinically important differences (MCID) (increases from 
baseline ≥ 5.0-points in domain and ≥ 2.5-points in physical and mental compo-
nent scores [PCS and MCS]) are presented. Results: Mean PCS and MCS scores 
across all groups increased from baseline through EMBLEM™ Week 12, with greater 
increases in the PBO group. Longer epratuzumab treatment during OLE resulted 
in clinically meaningful changes in HRQoL vs EMBLEM™ baseline. Mean PCS/MCS 
scores were 34.2/36.1, 38.7/40.0, 40.1/41.6 and 40.5/40.9 at EMBLEM™ baseline, OLE 
screening, Week 48 and Week 108, respectively. At OLE Week 108 70.8% and 59.3% 
of patients reported improvements ≥ MCID in PCS and MCS scores. ConClusions: 
therapeutic areas (classified according to the ICD-10) and 67 different indications. 
The most represented therapeutic areas were neoplasms (28 products, 40.6%) and 
endocrine, nutritional and metabolic diseases (21 products, 30.4%). Out of the 69 
products, 14 had a PRO claim (20.3% – in comparison, for all EMA products, the 
percentage is 26.9%). PROs identified in the claims were assessing function (e.g., 
physical functioning), symptoms (e.g., pain) and quality of life (QOL). Corresponding 
therapeutic areas and indications were neoplasms (trabectedin, ofatumumab, 
ruxolitinib), endocrine diseases (aztreonam lysine, ivacaftor, tafamidis), nervous 
system diseases (stiripentol, rufinamide), blood diseases (eculizumab, icatibant), 
pulmonary arterial hypertension (bosentan monohydrate, ambrisentan), cryopyrin-
associated periodic syndromes (rilonacept), and severe pain (ziconotide). Within 
these 14 products, four have a QOL claim (28.6%): two for neoplasms [trabectedin 
(ovarian cancer) – no differences between treatment in QOL; and ruxolitinib (mye-
olofibrosis) - improvement of QOL], one in diseases of the blood [eculizumab (two 
indications: paroxysmal nocturnal haemoglobinuria and atypical haemolytic urae-
mic syndrome - improvement of QOL], and one in endocrine disease [tafadimis 
(amyloidosis) – improvement of QOL]. ConClusions: The number of PRO claims in 
orphan medicines is comparable to the number of PRO claims in all EMA products. 
Various concepts are assessed, with QOL representing almost 30% of the claims.
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econoMic buRden of hand, foot and Mouth diSeaSe (hfMd) in china
Zheng Y, Yang J, Yu H
China CDC, Beijing, China
objeCtives: To estimate direct and indirect costs associated with hand, foot and 
mouth disease (HFMD) in China. Methods: Data were obtained from a nation-
wide telephone survey of family member of patients with HFMD from Dec, 2013 
to Jan, 2014. Patients’ numbers were from national infection disease surveillance 
database. Patients were eligible for the survey if they aged from 6 months to 5 years, 
had lab-confirmed as EV71, CoxA16 or other Enterovirus infection and without any 
underlying disease. HFMD-related outpatient and inpatient utilization and costs 
and direct non-medical costs were recorded. Indirect costs resulting from produc-
tivity loss due to absenteeism were estimated using the average income in China. 
All costs were reported in 2012 US dollar using the exchange rate of 6.18 Chinese 
Yuan to 1 USD. Results: A total of 3500 patients were included with 34.3% female. 
The number of mild, severe and death cases were 2259(64.54%), 1170(33.43%) and 
71(2.03%). 2352(67.23%) of patients received inpatient treatment. The mean direct 
medical costs were $966. Inpatient costs were $904, accounting for 93.5% of direct 
medical costs. The rest were attributed to outpatient and medications purchased 
from retail pharmacies. Mean direct non-medical costs were $67, including $20 
nutrition costs and $47 transportation. Mean costs associated with productivity 
loss were $170 and $55 (urban and rural respectively). ConClusions: HFMD poses 
substantial economic burden to payers, patients and society. The majority of total 
costs are attributed to direct medical costs but indirect costs from productivity loss 
are also substantial.
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1Oxford Outcomes, an Icon plc company, San Francisco, CA, USA, 2Oxford Outcomes, an Icon plc 
company, Oxford, UK, 3Amgen, Inc., Thousand Oaks, CA, USA
objeCtives: The purpose of this literature review was to identify existing patient 
reported outcome (PRO) instruments, instrument items, and concepts employed 
in studies of health-related quality of life (HRQoL) and PROs in anemia of ESRD. 
The results will aid the development of a PRO for the assessment of HRQoL in this 
therapeutic area. Methods: Relevant abstracts for inclusion were identified via 
a search in OVID (MEDLINE 1946 to present; EMBASE 1988 to present) using terms 
related to: anemia, HRQoL, PRO, ESRD, chronic kidney disease (CKD), and renal insuf-
ficiency. Results were limited to English-language, non-animal studies, and adult 
samples. Articles focusing on treatment effects and non-relevant diseases, confer-
ence abstracts and duplicate articles were excluded. Results: The search identified 
1764 abstracts. 1752 were excluded based on pre-specified criteria. Only 12 met the 
inclusion criteria. No ESRD anemia-specific PROs were identified. The most fre-
quently utilized PROs applied in ESRD anemia included the Kidney Disease Quality 
of Life and the Kidney Disease Quality of Life Short Form. Key concepts reflected 
direct patient experiences and disease impacts, and covered three domains: physi-
cal, mental/emotional, and social. Specific concepts within the domain of physical 
health included physical function, pain, fatigue, sleep disturbance, and sexual func-
tion. Concepts within the domain of mental/emotional health included emotional 
distress, cognitive effects, and satisfaction with life. Concepts within the domain 
of social health included ability or willingness to participate in social activities, and 
disease impacts on social relationships and work status. ConClusions: No PROs 
developed in ESRD-related anemia or published studies exploring HRQoL of anemic 
ESRD patients were found. The results of this literature review highlight the absence 
of in-depth qualitative examinations of patient experiences of ESRD-related anemia, 
as well as the lack of disease-specific PRO instruments. Relevant concepts identi-
fied may be useful to inform the development of ESRD anemia-specific PRO tools.
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objeCtives: Within New Mexico (NM) half of adults are either overweight or obese. 
Obesity is associated with low socioeconomic status, sedentary life style and several 
diseases; all pose a threat on general health. In order to rule out potential confound-
ing, we use propensity score matching to compare self-reported health of obese 
individuals with those of non-obese. Methods: We utilized data from the 2011 
